PERSONALIS INC (PSNL)       3.64  +0.28 (+8.33%)

3.64  +0.28 (+8.33%)

US71535D1063 - Common Stock - After market: 3.17 -0.47 (-12.91%)

PERSONALIS INC3.64

NASDAQ:PSNL (10/4/2022, 7:00:01 PM)+0.28 (+8.33%)

After market: 3.17 -0.47 (-12.91%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-03 2022-08-03/amc Earnings (Next) 11-02 2022-11-02
Ins Owners 2.68% Inst Owners 61.92%
Market Cap 167.14M Shares 45.92M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 83.08
IPO 06-20 2019-06-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PSNL Daily chart

Company Profile

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Company Info

PERSONALIS INC

1330 O'brien Drive

Menlo Park CALIFORNIA 94025

P: 16507521300.0

CEO: John West

Employees: 325

Website: http://www.personalis.com/

PSNL Twits

Here you can normally see the latest stock twits on PSNL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example